BLISS BIOPHARMACEUTICAL ENTERS INTO CLINICAL TRIAL COLLABORATION…
HANGZHOU, China, May 7, 2023 /PRNewswire/ — Bliss Biopharmaceutical (Hangzhou) Co., Ltd, (“BlissBio”), a clinical-stage biopharmaceutical company developing differentiated antibody-drug conjugate (ADC) therapeutics, announced a